Business UpdateJun 26, 2026, 03:53 PM
Stryker Recasts Financials for New Ortho Tech Segment
AI Summary
Stryker Corporation announced a change in its organizational structure in Q1 2026, creating a new Ortho Tech business by combining its orthopaedic instruments portfolio with Mako and other enabling technologies. This reorganization aims to simplify the customer experience and increase speed to market through focused innovation. Following this, Stryker will continue to have two reportable segments: MedSurg and Neurotechnology, and Orthopaedics. The company has recast its consolidated financial statements for the three years ended December 31, 2025, to reflect these segment reporting changes, which is for informational purposes and not a restatement of prior financials.
Key Highlights
- Stryker created a new Ortho Tech business combining orthopaedic instruments with Mako and enabling technologies.
- The company will continue to operate with two reportable segments: MedSurg and Neurotechnology, and Orthopaedics.
- Stryker recast consolidated financial statements for 2023, 2024, and 2025 to reflect segment reporting changes.
- The recast is for informational purposes and does not represent a restatement of previously issued financials.
- MedSurg and Neurotechnology net sales in 2025 were $13,692 million, up 16.5% from 2024.
- Orthopaedics net sales in 2025 were $11,424 million, up 5.4% from 2024.
- Consolidated net sales in 2025 reached $25,116 million, an 11.2% increase from 2024.
- Net earnings for 2025 were $3,246 million, with diluted EPS of $8.40.
Price Impact
More from SYK